leisure time -WSS

leisure time

author：focus 2025-08-23 08:57:13 - browse：191

BRENDAN SMIALOWSKI/AFP via Getty Images

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years.

Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its products for thousands of dollars more than it otherwise could. From 2017 to 2020, the company sold nearly 8,000 devices with the non-functioning component.

STAT published new details about the Stimwave story last May, after former employees described how Perryman broke into Stimwave’s Florida headquarters to steal back devices after her termination in 2019. The fraud laid bare the limits of the Food and Drug Administration’s device surveillance system, doctors’ ability to scrutinize device effectiveness, and how impossible it is for patients to get answers about the implants they receive.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： JPM 2024: Verve Therapeutics looks to mainstream genome editing

Wikipedia

WSS

New menopause drug shows promise in relief for hot flashes

What causes osteoarthritis? Researchers study link to brain protein

A pediatrician calls for Congress to pass the child tax credit deal

New Medicare drug pricing powers could soon be upended in court

What causes osteoarthritis? Researchers study link to brain protein

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Wikipedia

leisure time

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Maisha Meds is a PBM, but don't call it that

Virginia high school admissions case could be legal follow

HHS names first

Activists slam private health insurers over coverage restrictions

The nurse manager staffing crisis is hurting patients

The high cost of giving birth even with insurance

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Sports medicine is finally prioritizing gender equality

HHS names first

hotspot

New menopause drug shows promise in relief for hot flashes

Maisha Meds is a PBM, but don't call it that

High breast density mammograms need follow

Prior authorization reform is both possible and imperative

Inaction leaves children at risk from dangerous chemotherapy drug

GSK to buy asthma

leisure time

knowledge

focus

focus